Terms: = Ovarian cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract] [Full Text] [Related]
3. Single nucleotide polymorphisms in the D-loop region of mitochondrial DNA are associated with epithelial ovarian cancer prognosis.
Kong D; Shi S; Li Y
Mitochondrial DNA; 2015; 26(6):848-50. PubMed ID: 24409896
[TBL] [Abstract] [Full Text] [Related]
4. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.
Quick CM; May T; Horowitz NS; Nucci MR
Int J Gynecol Pathol; 2012 Jul; 31(4):337-43. PubMed ID: 22653347
[TBL] [Abstract] [Full Text] [Related]
